Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

AIMS: Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial end). It is unknown whether legacy effects follow a short period of very low low-density lipoprotein cholesterol (LDL-C) levels achieved with statin...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Bujas-Bobanovic, Maja, Diaz, Rafael, Fazio, Sergio, Fras, Zlatko, Goodman, Shaun G, Harrington, Robert A, Jukema, J Wouter, Manvelian, Garen, Pordy, Robert, Ray, Kausik K, Scemama, Michel, White, Harvey D, Steg, Ph Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119028/
https://www.ncbi.nlm.nih.gov/pubmed/36879424
http://dx.doi.org/10.1093/eurheartj/ehad144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119028/
https://www.ncbi.nlm.nih.gov/pubmed/36879424
http://dx.doi.org/10.1093/eurheartj/ehad144

Ejemplares similares